Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: A comprehensive meta-review

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 8, 2007, Pages 798-809

  Mina, Ashraf ^a,b   Favaloro, Emmanuel J ^a   Koutts, Jerry ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b New South Wales Institute of Sport   (Australia)

Author keywords

Adhesion molecules; Endocrine disorders; Endothelium; Hemostasis; Platelets

Indexed keywords

ALPHA TOCOPHEROL; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; LUPUS ANTICOAGULANT; NITRIC OXIDE; OMEGA 3 FATTY ACID; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOMATOMEDIN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ALCOHOL CONSUMPTION; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DAMAGE; CELL FUNCTION; CELL INTERACTION; CORONARY ARTERY DISEASE; CYTOLOGY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; ENDOCRINE DISEASE; ENDOCRINE SYSTEM; ENDOMETRIUM CANCER; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; ENDOTHELIUM; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; INSULIN RESISTANCE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; MULTIPLE SCLEROSIS; NEUROPATHY; OBESITY; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PREECLAMPSIA; PRIORITY JOURNAL; REPERFUSION; REVIEW; RISK FACTOR; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROID CANCER; THYROID DISEASE; VON WILLEBRAND DISEASE;

BLOOD PLATELETS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CELL ADHESION MOLECULES; DIABETES COMPLICATIONS; ENDOCRINE SYSTEM DISEASES; ENDOTHELIAL CELLS; HEMOSTASIS; HEMOSTATIC DISORDERS; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; NITRIC OXIDE; OXIDATIVE STRESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; SEROTONIN; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 38549101510     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1000372     Document Type: Review

References (81)

1. Tomoriova E, Tkac I, Takac M. Hypercoagulation states. Vnitr Lek 1993;39:1114-1119
2. Schafer AI. The hypercoagulable states. Ann Intern Med 1985;102:814-828
3. Palumbo PJ. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998;12:110-119
4. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998;158:617-621
5. Clemetson KJ. Platelet receptors and their role in diseases. Clin Chem Lab Med 2003;41:253-260
6. Packham MA, Mustard JF. The role of platelets in the development and complications of atherosclerosis. Semin Hematol 1986;23:8-26
7. Nordt TK, Bode C. Endothelium and endogenous fibrinolysis. Z Kardiol 2000;89:219-226
8. Becker BF, Heindl B, Kupatt C, Zahler S. Endothelial function and hemostasis. Z Kardiol 2000;89:160-167
9. Sumpio BE, Riley JT, Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol 2002;34:1508-1512
10. Nabel EG. Biology of the impaired endothelium. Am J Cardiol 1991;68:6C-8C
11. Berkenboom G. Vascular endothelium: target organ of cardiovascular pathologies. Ann Cardiol Angeiol (Paris) 1999;48:643-646
12. Mancini M, Rubba P. Ischemic cardiopathy: risk factors and their biological role. Ital Heart J 2000;1(Suppl 2):17-22
13. Simon BC, Noll B, Maisch B. Endothelial dysfunction-assessment of current status and approaches to therapy. Herz 1999;24:62-71
14. Willerson JT. Conversion from chronic to acute coronary heart disease syndromes. Role of platelets and platelet products. Tex Heart Inst J 1995;22:13-19
15. Vallance P, Calver A, Collier J. The vascular endothelium in diabetes and hypertension. J Hypertens Suppl 1992;10:S25-S29
16. Mehta JL, Nicolini FA, Donnelly WH, Nichols WW. Platelet-leukocyte- endothelial interactions in coronary artery disease. Am J Cardiol 1992;69:8B-13B
17. Harrison DG, Kurz MA, Quillen JE, Sellke FW, Mugge A. Normal and pathophysiologic considerations of endothelial regulation of vascular tone and their relevance to nitrate therapy. Am J Cardiol 1992;70:11B-17B
18. Pomilio M, Mohn A, Verrotti A, Chiarelli F. Endothelial dysfunction in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002;15:343-361
19. Horstman LL, Jy W, Jimenez JJ, Ahn YS. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci 2004;9:1118-1135
20. Krieglstein CF, Granger DN. Adhesion molecules and their role in vascular disease. Am J Hypertens 2001;14:44S-54S
21. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006;95:49-55
22. Blann AD, McCollum CN. von Willebrand factor, endothelial cell damage and atherosclerosis. Eur J Vasc Surg 1994;8:10-15
23. Blann A. Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci 1993;50:125-134
24. Lip GY, von Blann A. Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997;34:255-265
25. van Mourik JA, Romani de Wit T. Von Willebrand factor propeptide in vascular disorders. Thromb Haemost 2001;86:164-171
26. Nitu-Whalley IC, Lee CA. Acquired von Willebrand syndrome-report of 10 cases and review of the literature. Haemophilia 1999;5:318-326
27. Rinder MR, Richard RE, Rinder HM. Acquired von Willebrand's disease: a concise review. Am J Hematol 1997;54:139-145
28. Jakway JL. Acquired von Willebrand's disease. Hematol Oncol Clin North Am 1992;6:1409-1419
29. Delonca J, Balteaux V, Giraud T, Sanchez RY. EDRF/NO and endothelial functions. Arch Mal Coeur Vaiss 1993;86:1617-1624
30. Hunley TE, Iwasaki S, Homma T, Kon V. Nitric oxide and endothelin in pathophysiological settings. Pediatr Nephrol 1995;9:235-244
31. Vapaatalo H, Mervaala E. Clinically important factors influencing endothelial function. Med Sci Monit 2001;7:1075-1085
32. Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 2005;26:33-65
33. Rush JW, Denniss SG, Graham DA. Vascular nitric oxide and oxidative stress: determinants of endothelial adaptations to cardiovascular disease and to physical activity. Can J Appl Physiol 2005;30:442-474
34. Banfi C, Mussoni L, Tremoli E. PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms. Minerva Endocrinol 2002;27:181-191
35. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 2002;25:899-904
36. Malenfant M. Diabetic retinopathy: pathogenesis, risk factors, clinical picture, classification. Bull Soc Belge Ophtalmol 1995;256:11-23
37. Hano T, Nishio I. Hypertension in the patients with impaired glucose tolerance. Nippon Rinsho 1996;54:2687-2691
38. Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993;42:1-7
39. Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly 2002;132:241-252
40. Wirth A, Rothenfelde B. Metabolic syndrome. Versicherungsmedizin 1996;48:193-199
41. Dunn EJ, Grant PJ. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med 2005;5:323-332
42. Banga JD. Coagulation and fibrinolysis in diabetes. Semin Vasc Med 2002;2:75-86
43. Frohlich J, Steiner G. Dyslipidaemia and coagulation defects of insulin resistance. Int J Clin Pract Suppl 2000;113:14-22
44. Ghosh K. Thrombohaemorrhagic balance in diabetes mellitus. J Indian Med Assoc 2002;100:428-433
45. Ferrannini E, Galvan AQ, Gastaldelli A, et al. Insulin: new roles for an ancient hormone. Eur J Clin Invest 1999;29:842-852
46. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996;28:371-380
47. Janka HU. Insulin resistance and cardiovascular complications. Wien Klin Wochenschr 1994;106:758-762
48. Blann AD, Lip GY. Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes mellitus. Diabet Med 1998;15:634-642
49. Porta M, Molinatti P, La Selva M, Molinatti GM. Endothelium and its morphofunctional changes in the pathogenesis of diabetic microangiopathy. Minerva Med 1988;79:915-929
50. McMillan DE. The effect of diabetes on blood flow properties. Diabetes 1983;32(Suppl 2):56-63
51. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001;15:44-54
52. McDonagh PF, Hokama JY. Microvascular perfusion and transport in the diabetic heart. Microcirculation 2000;7:163-181
53. Sobol AB, Watala C. The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract 2000;50:1-16
54. Varughese GI, Tomson J, Lip GY. Type 2 diabetes mellitus: a cardiovascular perspective. Int J Clin Pract 2005;59:798-816
55. Luscher TF, Oemar BS, Yang Z, Noll G. Molecular and cellular mechanisms of arteriosclerosis and restenosis: possibilities of gene therapy. Z Kardiol 1996;85:495-508
56. Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2005;2:16-23
57. Arjomand H, Roukoz B, Surabhi SK, Cohen M. Platelets and antiplatelet therapy in patients with diabetes mellitus. J Invasive Cardiol 2003;15:264-269
58. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003;26:2181-2188
59. Kirpichnikov D, Sowers JR. Diabetes mellitus and diabetes-associated vascular disease. Trends Endocrinol Metab 2001;12:225-230
60. Savage PJ. Treatment of diabetes mellitus to reduce its chronic cardiovascular complications. Curr Opin Cardiol 1998;13:131-138
61. McMillan DE. Deterioration of the microcirculation in diabetes. Diabetes 1975;24:944-957
62. Kessler L, Wiesel ML, Attali P, Mossard JM, Cazenave JP, Pinget M. Von Willebrand factor in diabetic angiopathy. Diabetes Metab 1998;24:327-336
63. Porta M, La Selva M, Molinatti PA. von Willebrand factor and endothelial abnormalities in diabetic microangiopathy. Diabetes Care 1991;14:167-172
64. Bell DS. Alcohol and the NIDDM patient. Diabetes Care 1996;19:509-513
65. Lyons D. Impairment and restoration of nitric oxide-dependent vasodilation in cardiovascular disease. Int J Cardiol 1997;62(Suppl 2):S101-S109
66. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991;54:438-463
67. Gerster H. Prevention of platelet dysfunction by vitamin E in diabetic atherosclerosis. Z Ernahrungswiss 1993;32:243-261
68. Hirano T. Lipoprotein abnormalities in diabetic nephropathy. Kidney Int Suppl 1999;71:S22-S24
69. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132:989-993
70. Zdrojewicz Z, Sztuka-Piefkiewicz A, Zarzycki A, Karwacki J. Serotonin-structure, activity and clinical significance. Postepy Hig Med Dosw 1998;52:637-654
71. McCarty MF. Up-regulation of endothelial nitric oxide activity as a central strategy for prevention of ischemic stroke - just say NO to stroke!. Med Hypotheses 2000;55:386-403
72. Ferns GA, Motani AS, Anggard EE. The insulin-like growth factors: their putative role in atherogenesis. Artery 1991;18:197-225
73. Tschudi MR, Noll G, Luscher TP. Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors. Schweiz Med Wochenschr 1997;127:636-649
74. Mombouli JV. ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide. Drugs 1997;54(Suppl 5):12-22
75. Koppel H, Eber B, Gasser R, Klein W. Recent molecular and pharmacologic aspects of ACE inhibitors. Wien Med Wochenschr 1995;145:633-637
76. Ridker PM. Intrinsic fibrinolytic capacity and systemic inflammation: novel risk factors for arterial thrombotic disease. Haemostasis 1997;27(Suppl 1):2-11
77. Klein M, Barbe F, Kaminsky P, Duc M. Disorders of hemostasis in dysthyroidism. Pathol Biol (Paris) 1993;41:268-275
78. Ford HC, Carter JM. Haemostasis in hypothyroidism. Postgrad Med J 1990;66:280-284
79. Squizzato A, Romualdi E, Buller HR, Gerdes VE. Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab 2007;92:2415-2420
80. Squizzato A, Gerdes VE, Ageno W, Buller HR. The coagulation system in endocrine disorders: A narrative review. Intern Emerg Med 2007;2:76-83
81. Michiels JJ, Schroyens W, Berneman Z, van der Planken M. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine. Clin Appl Thromb Hemost 2001;7:113-115